Menu Search
Equities

Innate Pharma SA

0EVI:LSE

Innate Pharma SA

Actions
  • Price (EUR)1.63
  • Today's Change0.012 / 0.74%
  • Shares traded3.00k
  • 1 Year change-31.38%
  • Beta--
Data delayed at least 20 minutes, as of Nov 07 2024 11:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Innate Pharma SA grew revenues 4.68% from 49.58m to 51.90m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -58.10m to -7.57m.
Gross margin88.00%
Net profit margin-137.03%
Operating margin-155.27%
Return on assets-19.43%
Return on equity-78.59%
Return on investment-24.80%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Innate Pharma SA fell by 13.62m. However, Cash Flow from Investing totalled 20.63m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 32.56m for operations while cash used for financing totalled 1.97m.
Cash flow per share-0.3898
Price/Cash flow per share--
Book value per share0.3557
Tangible book value per share0.3543
More ▼

Balance sheet in EURView more

Innate Pharma SA has a Debt to Total Capital ratio of 75.27%, a lower figure than the previous year's 146.63%.
Current ratio2.92
Quick ratio--
Total debt/total equity3.04
Total debt/total capital0.7527
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.